;PMID: 7078154
;source_file_1016.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..159] = [t:47..159]
;2)section:[e:163..222] = [t:163..222]
;3)sentence:[e:226..492] = [t:226..492]
;4)sentence:[e:493..631] = [t:493..631]
;5)sentence:[e:632..826] = [t:632..826]
;6)sentence:[e:827..999] = [t:827..999]
;7)sentence:[e:1000..1151] = [t:1000..1151]
;8)section:[e:1155..1199] = [t:1155..1199]

;section 0 Span:0..41
;J Steroid Biochem. 1982 Feb;16(2):157-63.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Steroid) (NNP:[10..17] Biochem)
        (.:[17..18] .) (CD:[19..23] 1982) (CC:[24..31] Feb;16-LRB-)
        (CD:[31..32] 2) (-RRB-:[32..33] -RRB-) (CD:[33..37] :157) (::[37..38] -)
        (CD:[38..40] 63) (.:[40..41] .)))

;sentence 1 Span:47..159
;Aromatization of 15 alpha and 16 alpha hydroxylated androgens in the human 
;placental using [1,2-3H]-substrates.
;[99..108]:substance:"androgens"
;[139..158]:substance:"[1,2-3H]-substrates"
(SENT
  (NP-HLN
    (NP (NN:[47..60] Aromatization))
    (PP (IN:[61..63] of)
      (NP
        (NP
          (ADJP
            (NML (CD:[64..66] 15) (SYM:[67..72] alpha))
            (ADJP-2 (-NONE-:[72..72] *P*)))
          (NML-1 (-NONE-:[72..72] *P*)))
        (CC:[73..76] and)
        (NP
          (ADJP
            (NML (CD:[77..79] 16) (SYM:[80..85] alpha))
            (ADJP-2 (VBN:[86..98] hydroxylated)))
          (NML-1 (NNS:[99..108] androgens)))))
    (PP-LOC (IN:[109..111] in)
      (NP (DT:[112..115] the) (JJ:[116..121] human) (NN:[123..132] placental)))
    (S-ADV
      (NP-SBJ (-NONE-:[132..132] *))
      (VP (VBG:[133..138] using)
        (NP (NNS:[139..158] -LSB-1,2-3H-RSB--substrates))))
    (.:[158..159] .)))

;section 2 Span:163..222
;Cantineau R, Kremers P, De Graeve J, Gielen JE, Lambotte R.
(SEC
  (FRAG (NNP:[163..172] Cantineau) (NNP:[173..175] R,) (NNP:[176..183] Kremers)
        (NNP:[184..185] P) (,:[185..186] ,) (NNP:[187..189] De)
        (NNP:[190..196] Graeve) (NNP:[197..199] J,) (NNP:[200..206] Gielen)
        (NNP:[207..209] JE) (,:[209..210] ,) (NNP:[211..219] Lambotte)
        (NNP:[220..222] R.)))

;sentence 3 Span:226..492
;This in vitro study reports data on the aromatization of [1,2-3H]-C19
;steroids  in the human term placenta [androstenedione (III), testosterone
;(IV), 15  alpha-hydroxy-androstenedione (V), 15 alpha-hydroxy-testosterone
;(VI), 16  alpha-hydroxy-androstenedione (VII)].
;[283..304]:substance:"[1,2-3H]-C19 steroids"
;[334..349]:substance:"androstenedione"
;[351..354]:substance:"III"
;[357..369]:substance:"testosterone"
;[371..373]:substance:"IV"
;[376..409]:substance:"15  alpha-hydroxy-androstenedione"
;[411..412]:substance:"V"
;[415..444]:substance:"15 alpha-hydroxy-testosterone"
;[446..448]:substance:"VI"
;[451..484]:substance:"16  alpha-hydroxy-androstenedione"
;[486..489]:substance:"VII"
(SENT
  (S
    (NP-SBJ (DT:[226..230] This)
      (ADJP (FW:[231..233] in) (FW:[234..239] vitro))
      (NN:[240..245] study))
    (VP (VBZ:[246..253] reports)
      (NP
        (NP (NNS:[254..258] data))
        (PP (IN:[259..261] on)
          (NP
            (NP (DT:[262..265] the) (NN:[266..279] aromatization))
            (PP (IN:[280..282] of)
              (NP (NN:[283..295] -LSB-1,2-3H-RSB--C19) (NNS:[296..304] steroids)))
            (PP-LOC (IN:[306..308] in)
              (NP (DT:[309..312] the) (JJ:[313..318] human) (NN:[319..323] term)
                  (NN:[324..332] placenta)))
            (PRN (-LRB-:[333..334] -LSB-)
              (NP (NN:[334..349] androstenedione)
                (PRN (-LRB-:[350..351] -LRB-)
                  (NP (CD:[351..354] III))
                  (-RRB-:[354..355] -RRB-)))
              (,:[355..356] ,)
              (NP (NN:[357..369] testosterone)
                (PRN (-LRB-:[370..371] -LRB-)
                  (NP (CD:[371..373] IV))
                  (-RRB-:[373..374] -RRB-)))
              (,:[374..375] ,)
              (NP
                 (CD:[376..378] 15)
                 (NN:[380..409] alpha-hydroxy-androstenedione)
                (PRN (-LRB-:[410..411] -LRB-)
                  (NP (CD:[411..412] V))
                  (-RRB-:[412..413] -RRB-)))
              (,:[413..414] ,)
              (NP
                 (CD:[415..417] 15) (NN:[418..444] alpha-hydroxy-testosterone)
                (PRN (-LRB-:[445..446] -LRB-)
                  (NP (CD:[446..448] VI))
                  (-RRB-:[448..449] -RRB-)))
              (,:[449..450] ,)
              (NP
                 (CD:[451..453] 16)
                 (NN:[455..484] alpha-hydroxy-androstenedione)
                (PRN (-LRB-:[485..486] -LRB-)
                  (NP (CD:[486..489] VII))
                  (-RRB-:[489..490] -RRB-)))
              (-RRB-:[490..491] -RSB-))))))
    (.:[491..492] .)))

;sentence 4 Span:493..631
;The hydroxylated androgens were  microbiologically synthesized from
;commercially radiolabelled  [1,2-3H]-androstenedione and testosterone.
;[510..519]:substance:"androgens"
;[589..613]:substance:"[1,2-3H]-androstenedione"
;[618..630]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ-2 (DT:[493..496] The) (VBN:[497..509] hydroxylated)
              (NNS:[510..519] androgens))
    (VP (VBD:[520..524] were)
      (ADVP (RB:[526..543] microbiologically))
      (VP (VBN:[544..555] synthesized)
        (NP-2 (-NONE-:[555..555] *))
        (PP (IN:[556..560] from)
          (NP
            (NP
              (ADJP-1 (RB:[561..573] commercially)
                      (VBN:[574..587] radiolabelled))
              (NN:[589..613] -LSB-1,2-3H-RSB--androstenedione))
            (CC:[614..617] and)
            (NP
              (ADJP-1 (-NONE-:[617..617] *P*))
              (NN:[618..630] testosterone))))))
    (.:[630..631] .)))

;sentence 5 Span:632..826
;Androstenedione and testosterone were  good substrates for the human
;placental aromatase (low Km values, high Vmax);  they strongly inhibited the
;15 and 16 hydroxylated androgens aromatizations.
;[632..647]:substance:"Androstenedione"
;[652..664]:substance:"testosterone"
;[676..686]:substance:"substrates"
;[711..720]:cyp450:"aromatase"
;[726..728]:quantitative-name:"Km"
;[742..746]:quantitative-name:"Vmax"
;[801..810]:substance:"androgens"
(SENT
  (S
    (S
      (NP-SBJ (NN:[632..647] Androstenedione) (CC:[648..651] and)
              (NN:[652..664] testosterone))
      (VP (VBD:[665..669] were)
        (NP-PRD
          (NP (JJ:[671..675] good) (NNS:[676..686] substrates))
          (PP (IN:[687..690] for)
            (NP (DT:[691..694] the) (JJ:[695..700] human)
                (NN:[701..710] placental) (NN:[711..720] aromatase)))
          (PRN (-LRB-:[721..722] -LRB-)
            (NP
              (NP (JJ:[722..725] low) (NN:[726..728] Km) (NNS:[729..735] values))
              (,:[735..736] ,)
              (NP (JJ:[737..741] high) (NN:[742..746] Vmax)))
            (-RRB-:[746..747] -RRB-)))))
    (::[747..748] ;)
    (S
      (NP-SBJ (PRP:[750..754] they))
      (ADVP (RB:[755..763] strongly))
      (VP (VBD:[764..773] inhibited)
        (NP (DT:[774..777] the)
          (NML
            (NML
              (ADJP (CD:[778..780] 15)
                (ADJP-2 (-NONE-:[780..780] *P*)))
              (NML-1 (-NONE-:[780..780] *P*)))
            (CC:[781..784] and)
            (NML
              (ADJP (CD:[785..787] 16)
                (ADJP-2 (VBN:[788..800] hydroxylated)))
              (NML-1 (NNS:[801..810] androgens) (NNS:[811..825] aromatizations)))))))
    (.:[825..826] .)))

;sentence 6 Span:827..999
;On  the other hand, these hydroxylated compounds acted as poor substrates and
;were  only non-competitive inhibitors of the androstenedione and testosterone
; aromatizations.
;[866..875]:substance:"compounds"
;[890..900]:substance:"substrates"
;[932..942]:substance:"inhibitors"
;[950..965]:substance:"androstenedione"
;[970..982]:substance:"testosterone"
(SENT
  (S
    (PP (IN:[827..829] On)
      (NP (DT:[831..834] the) (JJ:[835..840] other) (NN:[841..845] hand)))
    (,:[845..846] ,)
    (NP-SBJ (DT:[847..852] these) (VBN:[853..865] hydroxylated)
            (NNS:[866..875] compounds))
    (VP
      (VP (VBD:[876..881] acted)
        (PP-CLR (IN:[882..884] as)
          (NP (JJ:[885..889] poor) (NNS:[890..900] substrates))))
      (CC:[901..904] and)
      (VP (VBD:[905..909] were)
        (NP-PRD
          (NP (RB:[911..915] only)
            (ADJP (AFX:[916..919] non) (HYPH:[919..920] -)
                  (JJ:[920..931] competitive))
            (NNS:[932..942] inhibitors))
          (PP (IN:[943..945] of)
            (NP (DT:[946..949] the)
              (NML
                (NML (NN:[950..965] androstenedione)
                  (NML-1 (-NONE-:[965..965] *P*)))
                (CC:[966..969] and)
                (NML (NN:[970..982] testosterone)
                  (NML-1 (NNS:[984..998] aromatizations)))))))))
    (.:[998..999] .)))

;sentence 7 Span:1000..1151
;However, 15 alpha-hydroxy-androstenedione could not be  disregarded as a
;potential precursor of 15 alpha-hydroxylated estrogens in the  human
;placenta.
;[1009..1041]:substance:"15 alpha-hydroxy-androstenedione"
;[1118..1127]:substance:"estrogens"
(SENT
  (S
    (ADVP (RB:[1000..1007] However))
    (,:[1007..1008] ,)
    (NP-SBJ-1 (CD:[1009..1011] 15)
              (NN:[1012..1041] alpha-hydroxy-androstenedione))
    (VP (MD:[1042..1047] could) (RB:[1048..1051] not)
      (VP (VB:[1052..1054] be)
        (VP (VBN:[1056..1067] disregarded)
          (NP-1 (-NONE-:[1067..1067] *))
          (PP (IN:[1068..1070] as)
            (NP
              (NP (DT:[1071..1072] a) (JJ:[1073..1082] potential)
                  (NN:[1083..1092] precursor))
              (PP (IN:[1093..1095] of)
                (NP
                  (ADJP
                    (NML (CD:[1096..1098] 15) (SYM:[1099..1104] alpha))
                    (HYPH:[1104..1105] -) (VBN:[1105..1117] hydroxylated))
                  (NNS:[1118..1127] estrogens)))
              (PP-LOC (IN:[1128..1130] in)
                (NP (DT:[1131..1134] the) (JJ:[1136..1141] human)
                    (NN:[1142..1150] placenta))))))))
    (.:[1150..1151] .)))

;section 8 Span:1155..1199
;PMID: 7078154 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1155..1159] PMID) (::[1159..1160] :) (CD:[1161..1168] 7078154)
        (NN:[1169..1170] -LSB-) (NNP:[1170..1176] PubMed) (::[1177..1178] -)
        (NN:[1179..1186] indexed) (IN:[1187..1190] for)
        (NNP:[1191..1199] MEDLINE-RSB-)))
